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ABSTRACT 
 
The with-no-lysine (K) WNK kinases are master regulators of the Na+-(K+)-Cl- 
cotransporters, including the renal-specific NCC and NKCC2 cotransporters. The 
discovery of WNK463, an orally bioavailable pan-WNK kinase inhibitor that 
exploits unique structural properties of the WNK catalytic domain to achieve high 
affinity and kinase selectivity, illustrates a strategy of leveraging distinct kinase 
features to develop specific inhibitors and validates the genetic predictions of the 
in vivo pharmacology of WNK inhibition. 
 
  
Protein kinases are pathogenically mutated in multiple human diseases, including 
cancer, neuropsychiatric disorders, inflammatory conditions, infectious diseases, 
and cardiovascular diseases (1). Approximately one-third of all protein targets 
under investigation in the pharmaceutical industry are kinases; over 30 kinase 
inhibitors are approved for clinical use; and dozens of other kinase inhibitors are 
actively under investigation in clinical trials (2). Despite this, the available 
armamentarium of clinically used kinase inhibitors covers less than 15% of the 
kinome, and these are used overwhelming for oncological conditions (2). 
Compared to cancer in which lack of treatment is often lethal, the bar is set much 
higher for kinase drug discovery in chronic conditions, because exquisite target 
selectivity and a minimum of side effects are required to compete with existing 
therapies (1).  
 
Mutations in the serine-threonine kinases of the with-no-lysine (K) WNK family 
WNK1 (encoded by PRKWNK1) and WNK4 (encoded by PRKWNK4) cause an 
autosomal dominant form of thiazide-sensitive and NaCl-sensitive hypertension 
with hyperkalemia termed Gordon’s Syndrome, or pseudohypoaldosteronism 
type II (PHAII; OMIM # 614496) (3). The WNK kinases regulate blood pressure 
and electrolyte homeostasis by phosphorylating and activating two related Ste20-
type kinases termed STE20/SPS1-related proline/alanine-rich kinase (SPAK) and 
oxidative stress-responsive kinase 1 (OSR1), collectively referred to as 
SPAK/OSR1. Activated SPAK/OSR1 phosphorylate and stimulate the activities of 
two related cation-Cl- cotransporters in the kidney in the aldosterone-sensitive 
part of the nephron, the Na+-Cl- cotransporter NCC and the Na+-K+-2Cl- 
cotransporter NKCC2 (Figure 1A). NCC is inhibited by hydrochlorothiazide and 
NKCC2 is inhibited by the furosemide, respectively. These are two of the most 
commonly used drugs (and well tolerated) in clinical medicine for the treatment of 
hypertension and edema (fluid retention in tissues).  WNKs also regulate NKCC1 
and KCC2, cation-Cl- cotransporters critical for establishing Cl- homeostasis in 
the nervous system, and implicated in multiple diseases featuring neuronal 
excitability due to GABA disinhibition(4). These actions of the WNKs make them 
attractive candidates for the development of novel kinase inhibitors. 
 
Kinase of the WNK (with no lysine) family are different from other kinases, 
because of the unusual placement of the catalytic lysine residue in WNK 
isoforms (Lys233 of WNK1) compared the active site lysine in all other protein 
kinases (5). This peculiarity could theoretically be exploited to create WNK-
specific ATP-competitive kinase inhibitors. Indeed, Yamada et al. exploited these 
unique structural features to conduct a high throughput screen for inhibitors of 
WNK1 catalytic activity (6). They discovered the first orally bioavailable pan-WNK 
kinase inhibitor, WNK463, which exhibits both low nanomolar affinity and high 
kinase selectivity. By solving the X-ray -crystal structure of WNK463 with the 
kinase-dead mutant WNK1 S382A at 1.65Å resolution, Yamada et al. showed 
WNK463 contacts the hinge region of the ATP binding site by burrowing through 
a narrow tunnel to the back pocket of WNK1, which occurs because of the 
nonstandard placement of the catalytic Lys233 in the glycine-rich loop (Fig. 1A).  
 
Inhibition of WNK kinases promotes both diuresis and vasodilation, therefore 
these kinases have garnered much attention as potential targets for the 
development of antihypertensive agents. Mutations in WNK1 (encoded by 
PRKWNK1) and WNK4 (encoded by PRKWNK4) cause an autosomal dominant 
form of hypertension that is also associated with hyperkalemia termed Gordon’s 
Syndrome or pseudohypoaldosteronism type II (PHAII; OMIM # 614496) (3). The 
WNK kinases regulate blood pressure and electrolyte homeostasis by 
phosphorylating and activating two related Ste20-type kinases termed 
STE20/SPS1-related proline/alanine-rich kinase (SPAK) and oxidative stress-
responsive kinase 1 (OSR1), collectively referred to as SPAK/OSR1. Activated 
SPAK/OSR1 phosphorylate and stimulate the activities of two related cation-Cl- 
cotransporters in the kidney in the aldosterone-sensitive part of the nephron, the 
Na+-Cl- cotransporter NCC and the Na+-K+-2Cl- cotransporter NKCC2 (Fig. 1B).  
 
Yamada et al. tested WNK463 in a rat hypertension model (6). In spontaneously 
hypertensive rats, orally administered WNK463 significantly decreased blood 
pressure, facilitated a brisk diuresis, and reduced the phosphorylation of SPAK 
and OSR1. This proof-of-biology study is important, because it establishes the 
importance of the WNK kinase catalytic domain in blood pressure and electrolyte 
homeostasis and confirms predictions made by human and rodent genetics 
about the in vivo pharmacology of WNK kinase inhibition (7). Moreover, WNK463 
will be an important research reagent that will help illuminate CCC regulation and 
the role of this pathway in physiological processes. 
 
The development of WNK463 as a potential therapeutic was discontinued due to 
other unspecified effects beyond those reported in the cardiovascular and renal 
systems when administered to the rats  at higher concentrations (6). This is 
perhaps not surprising, because the WNK kinases (including WNK2 and WNK3, 
kinases that not mutated in PHAII) are present throughout the body, although 
some isoforms exhibit restricted distribution. For example, the HSN2 isoform of 
WNK1 is almost exclusively detected in the nervous system, including the spinal 
cord dorsal horn, and inactivating HSN2 mutations cause hereditary sensory and 
autonomic neuropathy type IIA (HSANII; OMIM #201300) (8). Pan-WNK 
inhibition might, therefore, affect physiological process beyond those of blood 
pressure and electrolyte homeostasis.  
 
With regard to alternative means to inhibit the WNK pathway, where to go from 
here? The WNK substrates SPAK and OSR1 play a critical role in controlling 
blood pressure, and SPAK-deficient mice have markedly reduced blood pressure 
yet are otherwise healthy. Genome-wide association studies of essential 
hypertension show a strong association with common variants of SPAK. The 
strategy of targeting the ATP-binding site of the SPAK/OSR1 raises concern 
regarding the ability to develop sufficiently selective inhibitors that do not 
suppress other kinases. The development of Closantel and STOCK1S-14279, 
ATP insensitive inhibitors, has introduced the possibility of developing inhibitors 
of WNKs signaling by binding to constitutively active or WNK-sensitive 
(T233E)SPAK(9) (Fig. 1B). 
 
Another approach is to target protein-protein interaction sites. SPAK possess a 
specific docking CCT domain that mediates the interaction with RFxV motifs 
present in WNKs, NCC, and NKCC2 (10) (Fig. 1B). A high resolution three-
dimensional structure of this domain complexed to the RFxV motif has been 
solved (11) (Fig. 1A). Screens have identified inhibitors that disrupt the CCT-
RFxV interaction (12) and, chemical modulation of these first generation 
inhibitors might yield compounds that could be used in vivo. Because the CCT 
domain is unique to SPAK and OSR1, targeting this interaction site would not be 
expected to inhibit other kinases, which could provide sufficient specificity and 
safety for use in the treatment of a chronic condition, such as hypertension. 
Other strategies that antagonize tissue-specific WNK isoforms, for example by 
targeting the unique HSN2 isoform to treat neuropathic pain (13), could minimize 
unwanted side effects in other organ systems. 
 
Major challenges remain for the development of therapeutically effective kinase 
inhibitors in non-oncological diseases, including the identification and validation 
of driver kinases in these conditions and the discovery of drugs with adequate 
selectivity and safety (2). Targeting kinases that, when mutated, disrupt human 
physiology (even in rare inherited forms of disease) is a good strategy for the 
development of personalized treatments (14). With eight members of the WNK 
kinase signaling pathway, including their upstream regulators  (the E3 ubiquitin 
ligases CUL3-KLHL3) and downstream targets  (SPAK and OSR1 and cation-Cl- 
cotransporters) are mutated in Mendelian forms of renal and central nervous 
system pathology (7), continued efforts at drug discovery targeting this pathway 
are most certainly warranted.  
 
 
Figure 1. Domains and sites important for regulation of and signaling 
through the WNK-SPAK/OSR1 pathway. (A) Left: The structure of WNK463 
bound to the kinase-dead mutant WNK1 S382A (PDB ID: 5DRB). Right: The 
structure of the SPAK CCT domain bound to the RFxV motif. (B) Proteins with 
slashes indicate that multiple isoforms have the same properties. For 
SPAK/OSR1, the residue numbering above the protein represents SPAK, and 
the residue numbering below represents OSR1. Kinase X refers to a yet 
unidentified kinase that is regulated by WNKs and mediates the direct 
phosphorylation and inhibition of Site-1 on the KCCs. STOCK1S-50699 is a 
small-molecule inhibitor that blocks the interaction between SPAK/OSR1 and 
WNK by binding to the CCT domain (12); Closantel and STOCK1S-14279 are 
SPAK (ATP insensitive) inhibitors, able to bind to constitutively active or WNK-
sensitive(T233E)SPAK (9); and WNK463 inhibits of WNK1 catalytic activity (6).  
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